You are using an outdated browser. Please upgrade your browser to improve your experience.


Ligand Summary
Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL­17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines.
Synonyms & Links
DrugCentral: 5179
LyCHI:  brodalumab

Target Activities